<DOC>
	<DOC>NCT01445860</DOC>
	<brief_summary>The purpose of this study is to estimate the effect of multiple oral doses of PF-03882845 on the pharmacokinetics of simvastatin and simvastatin acid in healthy, adult subjects.</brief_summary>
	<brief_title>Drug-Drug Interaction Study Of Effect Of PF-03882845 On Simvastatin Pharmacokinetics</brief_title>
	<detailed_description />
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Healthy males and/or females of nonchildbearing potential between the ages of 18 (or 21 based on countryspecific age of consent) and 60 years, inclusive, at Screening. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12lead ECG or clinical/safety laboratory tests. Body Mass Index (BMI) of 17.5 to 30.5 kg/m2 inclusive; and a total body weight &gt;50 kg (110 lbs). Use of CYP3A4 inhibitors (eg, ketoconazole, ciprofloxacin, diltiazem) or inducers (eg, pheytoin, carbamazepine) or substrate (eg, simvastatin, quinidine) within 28 days or 5 halflives (whichever is longer) prior to Day 1. Known history of hypersensitivity, allergy, severe adverse drug reaction or intolerance to simvastatin or other statins.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>DDI</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>